Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis

Next Previous
Trial Profile

A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eplontersen (Primary)
  • Indications Transthyretin-related hereditary amyloidosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MaesTTRo
  • Sponsors AstraZeneca

Most Recent Events

  • 07 Aug 2025 Planned number of patients changed from 1600 to 1850.
  • 03 Feb 2025 Planned End Date changed from 27 Jun 2031 to 29 Dec 2031.
  • 03 Feb 2025 Planned primary completion date changed from 27 Jun 2031 to 29 Dec 2031.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top